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Abstract 
Objective: Zoledronic acid and denosumab were funded by the Australian government for the management of 
osteoporosis at an equivalent price to alendronate. The price of alendronate has declined by around 65 %, but the 
price of the other two therapies has remained stable. Using data published since the listing, this paper reports current 
estimates of the value of denosumab compared to alendronate from an Australian health system perspective.
Methods: A cohort-based state transition model was developed that predicted changes in bone mineral density 
(BMD), and calibrated fracture probabilities as a function of BMD, age and previous fracture to estimate differences in 
costs and QALYs gained over a 10-year time horizon.
Results: The base-case incremental cost per QALY gained for denosumab versus alendronate was $246,749. There is 
a near zero probability that denosumab is cost-effective at a threshold value of $100,000 per QALY gained. If the price 
of denosumab was reduced by 50 %, the incremental cost per QALY gained falls to $50,068.
Discussion: Current Australian legislation precludes price reviews when comparator therapies come off patent. The 
presented analysis illustrates a review process, incorporating clinical data collected since the original submission to 
inform a price at which denosumab would provide value for money.
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Background
Osteoporosis is a disease of the bony structure in which 
there is demineralization leading to a reduction in bone 
density, and increased risk of fracture. The most common 
fractures occur at the hip, spine (vertebrae) and wrist and 
can lead to long-lasting pain, reduced mobility, disabil-
ity and sometimes death [1]. A recent burden of disease 
study estimated that there were 140,822 fractures due 
to osteoporosis and osteopenia in Australians in 2012, 
contributing to an annual cost of $2.75 billion, which is 
predicted to rise to $3.84 billion by 2022 [2].
The pharmaceutical benefits schedule (PBS) in Aus-
tralia lists denosumab, alendronate, risedronate, 
strontium and zoledronic acid for the treatment of post-
menopausal osteoporotic women. Zoledronic acid was 
recommended for listing in 2008 on the basis of equiva-
lence of effect with alendronate, whilst denosumab was 
accepted for listing on the basis of equivalence of effect 
with zoledronic acid in 2010. In 2012, the Australian gov-
ernment introduced the expanded and accelerated price 
disclosure (EAPD) program that has led to significant 
reductions in the prices the government pays for phar-
maceuticals once they come off patent [3]. Since 2010, 
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the price of alendronate has declined by around 65  %, 
whilst the prices of zoledronic acid and denosumab have 
remained stable. In the financial year 2014/15, the gov-
ernment spent $120 million and $108 million on zole-
dronic acid and denosumab, respectively.
In the absence of new evidence to support a claim of 
additional effectiveness for zoledronic acid or deno-
sumab compared to alendronate then neither ther-
apy provides value for money when priced above 
alendronate. A recent meta-analysis of alendronate and 
denosumab concluded that denosumab does not reduce 
fracture risk compared to alendronate, though the four 
trials only reported outcomes up to 12 months [4]. Frac-
ture risk may be improved over a longer time period due 
to differences in persistence to therapy. Zoledronic acid 
and denosumab are administered as a 6 monthly dose 
of subcutaneous injection, whilst alendronate is a once 
weekly oral regimen. Improvements in persistence as a 
result of the once 6 monthly dosing has been cited as a 
driver of increased effects for denosumab compared to 
alendronate [5].
Since the listing of denosumab on the PBS, an exten-
sion to the pivotal randomised placebo controlled trial 
of denosumab has been published [6], as well as a head-
to-head comparison of persistence to alendronate and 
to denosumab [7]. The aim of this paper is to incorpo-
rate differences in persistence to therapy in a cost-utility 
analysis of an intended 5  years of treatment with deno-
sumab compared to alendronate for post-menopausal 
women with osteoporosis. The analysis is reported from 
an Australian healthcare perspective, to assess whether 
denosumab (and by implication zoledronic acid) cur-




A cohort-based state transition model was developed to 
represent important clinical events associated with oste-
oporosis. Similar to previously published models [8, 9], 
the model structure differentiated between hip and non-
hip fractures, and between the year following a new frac-
ture and subsequent years (Fig. 1).
The probability of fracture in each model cycle was 
estimated as a calibrated function of BMD, age, and 
the experience of prior fractures. BMD at the femoral 
head was represented in the model, following the use of 
BMD at this site in published risk equation models [10]. 
Annual percentage changes in BMD were estimated for 
women persisting with denosumab and alendronate, and 
for women not on treatment, over the model’s 10-year 
time horizon.
The eligible population was representative of the pop-
ulation in the fracture reduction evaluation of deno-
sumab in osteoporosis every 6 months (FREEDOM) trial, 
which recruited women with mean age 72  years (range 
60–90  years), mean BMD T-score at the femoral neck 
of −2.15, and with 24 % of women having experienced a 
previous fracture [11].
A 10-year time horizon was specified on the basis of the 
advanced age of the eligible population, and the uncer-
tainty around long-term treatment effects and persis-
tence. An annual model cycle with half cycle corrections 
was selected because the input data and the calibration 
data reported annual values, and the relatively small risk 
of fracture reduces the bias of longer model cycles [12]. 
The analysis represented the perspective of the health-















Fig. 1 Model structure
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Input parameter values
Input parameter values were extracted from a range of 
sources, as described in Tables 1 and 2, and summarised 
in the following sections.
BMD
Table  2 presents the reported annual absolute per-
centage changes in femoral neck BMD for patients 
remaining on treatment and patients not on treatment. 
Parameter values for the respective groups were derived 
from the denosumab and placebo arms of an extension of 
the FREEDOM trial that reported changes in BMD over 
3 years for patients not on treatment and over 5 years for 
patients who received denosumab for up to 5 years and 
who had not missed more than one dose of denosumab 
over the initial 3 years [6]. Beyond 3 and 5 years respec-
tively, alternative constant annual absolute percentage 
changes in BMD were applied to patients not on treat-
ment and on treatment, which were estimated from the 
observed data.
Fracture risk
The model structure differentiates between the experi-
ence of hip and non-hip fractures, and represents fracture 
risk as a function of age, experience of previous fractures, 
and femoral neck BMD. Fractures of the skull, face, man-
dible, metacarpals, fingers, and toes, and fractures asso-
ciated with severe trauma were excluded because they 
are not associated with decreased BMD. A published 
fracture risk calculator was initially used to estimate frac-
ture probabilities [10], but the resulting model outputs 
did not converge to observed fracture rates in the deno-
sumab and placebo groups in the FREEDOM extension 
study [6]. Instead, the following quadratic equations were 
fitted to predict observed hip, and non-hip clinical frac-
ture probabilities:
where BMD represents the T-score at the femoral neck, 
Year denotes the year since treatment initiation (analo-
gous to age), PF indicates the experience of a previous 
fracture, and a to j are parameter values that were fitted 
as part of a calibration process.
Sets of values for parameters a to j were randomly 
sampled from ranges specified for each of the ten input 
parameters. The ranges were informed by analyses of 
the fracture risk assessment tool (FRAX) to inform the 
effects of age and previous fractures on fracture risk [10], 
combined with deterministic model analyses to identify 
equation parameter values that fitted the observed frac-
ture data. Convergence criteria were met when the model 

















= f (g .PF)(1+ h.Year)
+ i(−BMD − 1.9)j
P
(
non hip fracture|no PF
)
= f (1+ h.Year)
+ i(−BMD − 1.9)j
Table 1 Annual absolute percentage change in femoral neck BMD: observed data and scenarios for extrapolated
a Annual percentage changes in BMD assumed to be equal for patients remaining on treatment with either denosumab or alendronate
b Ref. [6]
c Base case extrapolations equal to average effects in last two years, sensitivity analyses based on average effect in last three years on treatment and in last year off 
treatment
Year On treatmenta Off treatment
Observedb Extrapolatedc Observedb Extrapolation scenariosc




4 0.98 −0.53 −0.69
5 0.34 −0.53 −0.69
6 0.66 0.87 −0.53 −0.69
7 0.66 0.87 −0.53 −0.69
8 0.66 0.87 −0.53 −0.69
9 0.66 0.87 −0.53 −0.69
10 0.66 0.87 −0.53 −0.69
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fractures at 3  years, in patients receiving denosumab 
and placebo), were all within the 95 % confidence inter-
vals of the observed data. Sampling continued until 5000 
convergent parameter sets were identified. Probability 
weights were assigned to the convergent sets using the 
reciprocal of the χ2 statistic across the four calibration 
targets [13]. The range of convergent values for the fitted 
parameter a to j are presented in Table 1.
Table 2 Model input parameter values
PBS pharmaceutical benefits schedule, MBS medicare benefits schedule (drug administration assumed to require one practice nurse visit—item 10997, annual 
follow-up requires one GP visit—item 36, and bone densitometry procedure—item 12306)
Parameters Mean Lower 95 % CI Upper 95 % CI Distribution Source
Annual non-persistence probability
Denosumab 0.098 0.05 0.15 Log normal [7]
Alendronate 0.202 0.14 0.28
Mortality relative risk (in 1st year after a fracture)
Hip fracture 2.43 2.02 2.93 Log normal [17]
Non-Hip fracture 1.65 1.52 2.17
Annual costs
Denosumab (2 × 60 mg/mL) $541.64 PBS
Administration $24.0 MBS
Alendronate (52 × 70 mg) $199.16 PBS
Annual follow-up $148.5 MBS
Hip fracture, year 1 $30,720 $24,576 $36,864 Log normal [2]
Hip fracture, year 2+ $3280 $2624 $3936
Non-hip fracture, year 1 $6593 $5274 $7912
Non-hip fracture, year 2+ $253 $202 $303
Utility values (no fracture)
Mean population value (age 
70–80 years)
0.8 0.78 0.82 Beta [21]
Utility multipliers
Hip fracture, year 1 0.70 0.64 0.77 Beta [5, 22]
Hip fracture, year 2+ 0.80 0.68 0.96
Non-hip fracture, year 1 0.84 0.75 0.92
Non-hip fracture, year 2+ 0.96 0.95 0.97
Fracture risk equations parameters
a [Constant coefficient for hip 
fractures]
0.0005 0.0003 0.0007 Probability weights assigned 
(based on χ2 statistic)
[10], final values fitted via model 
calibration [13]
b [Prev. fracture coefficient for hip 
fractures]
1.4979 1.2659 1.7379
c [Year coefficient for hip frac-
tures]
0.0699 0.0367 0.1031
d [(-BMD−1.98) coefficient for hip 
fractures]
0.0267 0.0159 0.0367
e [Exponent of (-BMD−1.98) for 
hip fractures]
1.5042 1.2651 1.7331
f [Constant coefficient for non-hip 
fractures]
0.0043 0.0022 0.0069
g [Prev. fracture coefficient for 
non-hip fractures]
1.4981 1.2631 1.7374
h [Year coefficient for non-hip 
fractures]
0.0698 0.0369 0.1033
i [(-BMD−1.98) coefficient for 
non-hip fractures]
0.1997 0.1377 0.2704
j [Exponent of (-BMD−1.98) for 
non-hip fractures]
1.4218 1.2146 1.5913
Page 5 of 10Karnon et al. Cost Eff Resour Alloc  (2016) 14:11 
Persistence
An intended treatment duration of 5 years is assumed 
for both alendronate and denosumab, but differences in 
persistence have been observed due to differences in the 
mode and frequency of administration. Persistence was 
defined as receiving two injections per year for deno-
sumab [7], whilst time to non-persistence for alendronate 
was based on the time of a patient’s last dose [14]. Persis-
tence on denosumab was estimated from the denosumab 
adherence preference satisfaction (DAPS) study, a crosso-
ver study that randomised 250 postmenopausal women to 
alendronate or denosumab [7]. To avoid contamination, 
persistence rates in the DAPS study prior to crossover 
were used, which were 9.5 % for denosumab and 20.2 % for 
alendronate. Similar non-persistence rates were reported 
for alendronate by a 12-month observational, multi-cen-
tre study of 6064 patients [14]. The approximately con-
stant rate of non-persistence over 12 months supports the 
application of the year 1 non-persistence rates to years 2 
to the maximum 5-year treatment duration.
Treatment offset
Continuing treatment effects beyond treatment discon-
tinuation have been analysed [15]. Extension data for 
alendronate show that BMD declined following treat-
ment cessation, and that over 5 years, continuation of 
alendronate was associated with significantly lower risk 
of both non-vertebral and clinical vertebral fractures 
in women with lower baseline BMD or prevalent verte-
bral fracture [16]. The current model reflects continuing 
treatment effects through the application of ‘no treat-
ment’ annual percentage changes to BMD following 
treatment discontinuation, which results in a gradual 
decline in BMD.
Mortality
Annual probabilities for mortality were derived from 
Australian life tables, with adjustment for increased mor-
tality risk in the year following a new fracture. Bliuc et al. 
reported standardized mortality ratios (SMRs) follow-
ing hip and non-hip major fractures, reporting that the 
effects were maintained beyond 10 years following a hip 
fracture and for 5 years following a non-hip fracture [17]. 
The cohort-based model structure precluded the exact 
application of the SMRs, so both reported SMRs were 
applied over the full 10-year time horizon.
Costs
Annual treatment costs for denosumab and alendronate 
were obtained from the Australian pharmaceutical ben-
efits schedule: AUD $541 per year for denosumab (a 
twice yearly 60 mg/mL injection) and AUD $199 for alen-
dronate (a 70 mg weekly oral drug) [www.pbs.gov.au]. To 
reflect the impact of patient co-payments, a sensitivity 
analysis was undertaken assuming all patients contrib-
uted $6.10 to each prescription (the current concession 
card holder contribution).
Treatment-related adverse events were not repre-
sented in the model because no statistically significant 
differences were observed in the main head-to-head trial 
of denosumab and alendronate [18]. Costs associated 
with the treatment of fractures, in the year following a 
new event, were derived from a recent Australian bur-
den of disease study [2]. Previous studies have reported 
ongoing costs, beyond the year in which a fracture is 
experienced, based on admissions to long-term aged 
care facilities [19]. The reported nursing home costs in 
the burden of disease report (the fracture-related prob-
ability of moving into a nursing home multiplied by 
the annual cost) were applied as ongoing costs beyond 
the year in which a fracture was experienced [2]. In the 
absence of empirical estimates of uncertainty around 
the cost estimates presented in the burden of disease 
study, 95 % confidence limits were arbitrarily assumed to 
be ±25 % of each mean value in line with other studies 
that have defined arbitrary levels of uncertainty [20].
Health‑related quality of life (utility) weights
Age-specific general population utility weights informed 
a mean utility weight of 0.8 over the 10-year time horizon 
for women not experiencing a fracture [21]. No Austral-
ian utility weights were identified for the fracture states, 
and so utility multipliers reported in a recent meta-anal-
ysis were used [22], supplemented with year 2 onwards 
multipliers for vertebral, wrist, and other fractures esti-
mated by Chau and colleagues [5]. A weighted non-hip 
fracture multiplier was estimated by applying weights to 
the clinical vertebral, and wrist and other fracture multi-
pliers based on the proportions of each type of fractures 
reported in the FREEDOM trial [11].
Analysis
The reference case analysis was informed by 5000 model 
runs, each informed by a set of input parameter values 
that were randomly sampled from the defined prob-
ability distributions, and the weighted sets of calibrated 
input parameters for the fracture risk equations [13]. 
The reference case outputs were analysed to generate 
mean estimates of costs and QALYs for denosumab and 
alendronate, the expected incremental cost-effectiveness 
ratio (ICER), as well as a cost-effectiveness acceptability 
curve. A comprehensive range of deterministic sensitiv-
ity analyses were also undertaken, testing the individual 
effects of key clinical, cost, and utility input parameters, 
as well as the effects of discounting and variations in 
price for denosumab.
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Results
Calibration analysis
Five thousand sets of convergent input parameter values 
were sampled from the specified ranges, each set pre-
dicted model outputs within the 95  % confidence inter-
vals for hip, and non-hip fracture probabilities at 3 years 
for patients receiving denosumab, and placebo in the 
FREEDOM trial [6]. The upper and lower bounds of the 
calibrated fracture-free survival curves are presented in 
Fig. 2, which show 10-year hip and non-hip probabilities 
of 0.34–0.42 for no treatment, and 5 year probabilities 
of 0.1–0.13 for patients remaining on denosumab for 5 
years. Increasing risk over time in the no treatment group 
is consistent with observational data that indicates risk 
increases with age in the non-treated population, whilst 
the trend towards decreasing risks with time for patients 
remaining on denosumab is consistent with the extension 
phase of the FREEDOM trial, which shows reducing frac-
ture risk in years 4 and 5, as BMD continues to increase.
Cost‑effectiveness analysis
In the base case analysis, the model predicted that 
24.7 and 28.5 new fractures would be experienced per 
100 patients allocated to denosumab and alendronate, 
respectively.
Table  3 presents the cost-effectiveness results from 
the base case analysis, as well as from a comprehensive 
set of deterministic sensitivity analyses. In the base case 
analysis, the mean difference in cost was $1446, which is 
around $300 less than the mean difference in interven-
tion costs due to lower fracture costs in the denosumab 
group. The reduced fracture probabilities also provide 
a gain of 0.006 QALYs per patient, which results in an 
expected ICER of $246,749 per QALY gained.
The deterministic sensitivity analyses show that the 
mean result is relatively stable to variation in most of 
the input parameters tested. The less conservative equa-
tion parameters and the lower 95  % confidence inter-
vals for the fracture SMR reduce the ICER to just under 
$200,000. In the absence of significant survival effects, 
the results are heavily influenced by the utility weights, 
with the ICER decreasing to $163,384 when the lower 
interval utility weights are applied to the fracture states. 
Reducing the price of denosumab by 50  % reduces the 
ICER to $50,068.
Figure  3 presents the cost-effectiveness acceptability 
curves, which show that at cost-effectiveness threshold 
of $100,000, there is a close to zero probability of deno-
sumab being cost-effective.
Discussion
This paper has presented an economic evaluation of den-
osumab compared to alendronate to re-assess the value 
of denosumab to the Australian community, which was 
evaluated for listing on the PBS in 2010. The analysis 
used data that has been published since 2010 to inform 
key model parameters and incorporates the significant 
price differential between denosumab and alendronate 
that has developed since alendronate went off-patent and 
was subject to the effects of the EAPD program.
Although there is some evidence of larger improve-



























Fig. 2 Calibrated fracture-free survival curves upper and lower bounds
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compared to alendronate, it appears to be a short-term 
effect [18]. The pharmaceutical benefits advisory com-
mittee (PBAC) have not previously accepted claims of 
superior clinical effect for patients receiving either zole-
dronic acid or denosumab compared to alendronate and 
in the absence of new clinical effectiveness data there is 
no reason to suppose that decision would change. How-
ever, improved persistence with denosumab and zole-
dronic acid implies that the effective comparator for both 
therapies is a mix of alendronate (for the proportion of 
patents who persist with alendronate) and no treatment 
(for the proportion of patients who persist with deno-
sumab or zoledronic acid but who would not persist with 
alendronate).
The base case results show that denosumab is unlikely 
to be considered cost-effective, with a mean ICER of 
$246,749 per QALY gained. Other than the price of deno-
sumab, deterministic sensitivity analyses showed that the 
Table 3 Results table
SMR standardized mortality ratio
Analysis Denosumab Alendronate Differences ICER
Costs QALYs Costs QALYs Costs QALYs
Base case $5483 5.823 $4037 5.817 $1446 0.006 $246,749
Risk fracture equation parameters:
Lower 95 % confidence limit ICER $5233 5.829 $3824 5.822 $1346 0.005 $191,164
Upper 95 % confidence limit ICER $5660 5.840 $4287 5.834 $1431 0.007 $282,342
% change in BMD sensitivity scenarios (see Table 1) $5534 5.812 $4123 5.805 $1411 0.006 $223,458
Year 3, 50 % of non-persistence in year 2 $5485 5.825 $4039 5.820 $1445 0.005 $272,323
Lower 95 % interval fracture SMR $5498 5.860 $4107 5.855 $1391 0.006 $243,293
Upper 95 % interval fracture SMR $5381 5.769 $3969 5.761 $1412 0.007 $197,015
Fracture costs × 0.75 $4943 5.828 $3494 5.822 $1449 0.006 $251,018
Fracture costs × 1.25 $5924 5.841 $4578 5.835 $1347 0.006 $217,746
Lower 95 % interval fracture utility multipliers $5462 5.801 $4077 5.792 $1385 0.008 $163,384
Upper 95 % interval fracture utility multipliers $5464 5.866 $4073 5.862 $1392 0.004 $378,871
‘No fracture’ utility = 1 $5447 7.292 $4056 7.284 $1390 0.007 $188,997
No discounting $6403 7.117 $4913 7.109 $1490 0.008 $181,755
All patients contribute $6.10 per prescription $5326 5.839 $3829 5.833 $1497 0.006 $260,582




























Fig. 3 Cost-effectiveness acceptability curves
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results were most sensitive to the assumed utility effects 
of fracture. The probabilistic sensitivity analysis shows a 
near zero probability of cost-effectiveness at a threshold 
value of $100,000 per QALY gained. Reducing the price 
of denosumab by 50 % brought the ICER down to around 
$50,000. PBAC has not explicitly defined a threshold 
for acceptable ICERs, but recent public summary docu-
ments suggest that ICERs are accepted if they are below 
or at the lower end of the range $45,000–$75,000 per 
QALY gained [23, 24]. The opportunity costs of thera-
pies in clinical areas such as osteoporosis are likely to be 
greater than the average due to the large budget impact 
of more expensive therapies, which suggests the price 
of denosumb should be reduced by more than 50  % in 
order to demonstrate value for money to the Australian 
community.
Five published evaluations of denosumab compared 
to alendronate were identified [5, 8, 9, 19, 25], which 
all reported significantly lower ICERs than the current 
analysis, ranging from approximately Aus$30,000 [8] 
to around Aus$100,000 [19]. The models differed with 
respect to intervention prices, baseline fracture risks, 
SMRs, costs and utility values following fracture, dis-
count rates and time horizons, but the main factor driv-
ing the order of magnitude difference in ICERs compared 
to the current study was an assumption of superior clini-
cal effectiveness for denosumab. All five studies referred 
to the same meta-analysis to estimate relative risks (RRs) 
for alendronate compared to placebo, whilst RRs for 
denosumab were all derived from the FREEDOM study 
[11]. This non-adjusted indirect comparison provides a 
low level of evidence of a superior clinical effect of deno-
sumab compared to alendronate, which was rejected by 
the PBAC.
In addition to the assumption of no superior clinical 
effectiveness, the model structure used in the current 
study differs significantly from the common approach 
used in the five reviewed evaluations [5, 8, 9, 19, 25]. The 
previous models all applied RRs to baseline fracture risk 
probabilities. An advantage of this direct application of 
fracture treatment effects is that it enables the use of frac-
ture data relevant to the population for whom a funding 
decision is being informed by the evaluation. However, it 
requires an assumption of constant treatment effects and 
subjective assumptions regarding carryover effects after 
cessation of treatment.
In the current model, hip and non-hip fracture risks 
were calibrated separately as non-linear functions of age, 
BMD and previous fractures. The fitted  age, BMD and 
previous fracture parameters reflect underlying changes 
in fracture risk as well as treatment effects. Whilst BMD 
is no longer considered a strong surrogate for frac-
ture risk [26], the multivariate, non-linear calibration to 
observed BMD values and fracture event rates in treated 
and non-treated cohorts uses BMD as a proxy for an 
underlying treatment effect. The calibration process 
reduces the subjectivity of model assumptions around a 
constant treatment effect and the treatment offset period.
The analysis was based on the FREEDOM trial popu-
lation [11], which reflects the PBS-listed indication for 
denosumab and alendronate. The mean age of the FREE-
DOM population was 70  years, which is similar to the 
mean age of the Australian population with diagnosed 
osteoporosis [27]. The fracture rates observed in the trial 
are unlikely to differ significantly from an equivalent Aus-
tralian population, and the base case result was not sensi-
tive to varying fracture risks.
The 10-year time horizon may omit some important 
differences in costs and outcomes between the com-
parators, as 75 % of the cohort remain alive at 10 years. 
However, given the modelled 5-year treatment dura-
tion, a 10-year horizon was selected on the basis that 
any residual treatment effect is likely to have dissipated 
after 5 years without treatment. A longer time horizon, 
and some adjustments to the model would be required 
to estimate the effects of continuing treatment beyond 
5 years for patients remaining at elevated risk of fracture. 
The persistence input parameters were informed by sur-
vival plots over 12 months, but these parameters could be 
further informed by analyses of individual level PBS data 
to estimate real-world persistence over multiple years.
This paper has illustrated the effects of price differen-
tials that emerge over time between pharmaceuticals that 
are listed on the PBS on a cost minimization basis and 
their comparator therapies. Recent analyses of PBS data 
suggest that savings of over $500 million per year could 
be realized if the government stopped paying differen-
tial prices for pharmaceuticals with equivalent effects 
[3]. Price differentials arise as comparator pharmaceu-
ticals come off patent and are subject to price competi-
tion, whilst pharmaceuticals that remain on patent are 
protected from price competition. There are legislative 
and related political barriers to addressing this issue. Leg-
islation was introduced in 2007 that protects the price of 
pharmaceuticals when their comparator goes off patent 
by effectively blocking reference pricing between pat-
ented and non-patented pharmaceuticals [28]. Interna-
tional trade agreements, with background influence from 
the patented-pharmaceutical industry in Australia and 
overseas illustrate the more general political hurdles that 
need to be overcome.
From a practical perspective, a review date could be 
specified for listed pharmaceuticals as their compara-
tor comes off patent, to update decisions on the basis 
of the lower comparator cost as well as any new clinical 
and economic data. The analysis presented in this paper 
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illustrates a case in which a continuing but reduced price 
premium may be justified on the basis of an updated 
cost-effectiveness analysis using data published since the 
original submission. In most cases, expedited reviews are 
likely to be sufficient to demonstrate that there is no basis 
for a price premium.
Conclusions
Zoledronic acid and denosumab were funded by the 
Australian government for the management of osteopo-
rosis at an equivalent price to alendronate. The price of 
alendronate has declined by around 65 %, but the price 
of the other two therapies has remained stable. This 
paper has reviewed the cost-effectiveness of denosumab 
using data published since the listing to show that the 
current price of denosumab (and by implication zole-
dronic acid) should be reduced by more than 50  % to 
demonstrate value to Australian community. Current 
Australian legislation precludes price reviews once a 
therapy is listed on the PBS (unless requested by a man-
ufacturer), which means many listed pharmaceuticals 
are no longer providing value for money. The Australian 
government should act to enable a price review process 
to further improve the efficiency and sustainability of 
the PBS.
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